Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03994406 · ClinicalTrials.gov registry record · Phase 2
Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel
A Phase 2 study of Contact Lens Discomfort and Contact Lens-induced Corneal Disorder, sponsored by Glia.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03994406: Completed Phase 2 study of Contact Lens Discomfort and Contact Lens-induced Corneal Disorder, sponsored by Glia.
NCT03994406 is a Phase 2 study of Contact Lens Discomfort and Contact Lens-induced Corneal Disorder that has completed, run by Glia. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03994406, a Phase 2 study of Contact Lens Discomfort and Contact Lens-induced Corneal Disorder, has completed, sponsored by Glia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study compares contact lens comfortable wear duration, and signs and symptoms of contact lens discomfort, test versus control.
Primary Outcome
Change in total hours per day
Conditions Studied
Interventions
- DRUG CLM2 topical gel
- DRUG Placebo topical gel
Study Locations (1)
California
- UC Berkeley Clinical Research Center - Berkeley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2019-10-30 |
| Phase | Phase 2 |
What the finished NCT03994406 record still lists
NCT03994406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 4 conditions, with Contact Lens Discomfort appearing as the primary indexed condition, and to 2 interventions - of which CLM2 topical gel is the first listed.
NCT03994406 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03994406 about?
NCT03994406 is a clinical study titled "Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel". This study compares contact lens comfortable wear duration, and signs and symptoms of contact lens discomfort, test versus control.
What is the current status of trial NCT03994406?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-06-27. Estimated completion is 2019-10-30.
What conditions does trial NCT03994406 study?
This clinical trial studies the following conditions: Contact Lens Discomfort, Contact Lens-induced Corneal Disorder, Contact Lens Acute Red Eye, Contact Lens-induced Corneal Fluorescein Staining.
What interventions are being tested in trial NCT03994406?
The interventions under investigation include: CLM2 topical gel (DRUG), Placebo topical gel (DRUG).
Who is sponsoring clinical trial NCT03994406?
This trial is sponsored by Glia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03994406 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contact Lens Discomfort
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03994406's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI